Jaguar Health Advances Rare Disease Treatment Following Promising Trial Results

2026-08-20 companies

San Francisco, Wednesday, 19 August 2026.
Jaguar Health reported promising trial data showing its drug crofelemer reduced intravenous nutritional support by up to 48% in children with a rare disease, driving plans for a 2027 FDA submission.

Clinical Progress Drives Strategic Timeline

Jaguar Health (NASDAQ: JAGX) reported second quarter 2026 financial results on August 19, 2026, highlighting significant progress in its global clinical development program for crofelemer [1]. The company showcased clinical trial data evaluating crofelemer as an adjunctive oral therapy for pediatric microvillus inclusion disease (MVID), which demonstrated up to a 48% reduction in required parenteral support normalized to body weight [1]. This data was presented at ESPGHAN 2026, underscoring the potential impact on patients with this ultrarare intestinal failure disease [1]. Based on these developments, Jaguar Health announced plans to finalize its New Drug Application (NDA) clinical package by the end of 2026, targeting a formal FDA submission in the second quarter of 2027 [1]. The company aims for regulatory approval and potential commercialization of its powder formulation of crofelemer used in rare disease Intestinal Failure (IF) clinical trials [1].

Second Quarter Financial Performance

On August 19, 2026, Jaguar Health reported Q2 2026 financial results, including a total net revenue of $1.225 million [1]. This figure represents a 59% decrease from Q2 2025, calculated as -58.879 based on reported prior year revenue of $2.979 million [4]. The company reported a Q2 2026 net loss attributable to common shareholders of $12.7 million for the period ending June 30, 2026, an increase from the $10.4 million loss recorded for the quarter ended June 30, 2025 [1]. Financial results also included $43,000 in license fees recognized from a European partner and $25,520 in federal grant revenue for a chemotherapy-induced diarrhea canine study [1]. The revenue decline reflects the transition of U.S. commercialization for Mytesi and Canalevia to Future Pak, which reduced Jaguar Health’s internal sales and marketing activities [4].

Licensing Agreements and Revenue Streams

In January 2026, Jaguar Health signed a U.S. commercial licensing agreement with Woodward Specialty, LLC, an affiliate of Future Pak, LLC [1]. Under this agreement, Future Pak became the exclusive U.S. marketer for Mytesi and Canalevia-CA1, resulting in an initial $16 million upfront payment and $3 million early termination fee recognized in Q1 2026 [1]. In August 2026, Jaguar satisfied closing conditions to receive a $2 million non-dilutive holdback payment from Future Pak related to the licensing agreement [1]. This strategic shift allows the company to scale back direct commercial operations while focusing resources on clinical development [4]. The company maintains an active S-3 shelf registration statement effective through October 3, 2028 [3].

Investor Communication and Market Activity

Jaguar Health scheduled an investor webcast for August 19, 2026, at 4:30 p.m. Eastern time to discuss Q2 2026 financials and company updates [1]. The company plans to file its Form 10-Q earnings report for the quarter ending June 30, 2026, on August 19, 2026 [3]. During the August 18, 2026, trading session, JAGX stock experienced an 11.10% increase, with a peak intraday gain of 24.8% and trading volume at 1.9x the daily average [3]. The webcast provides an opportunity for investors to gain insights into Jaguar’s financial performance and recent corporate developments [6]. A replay of the event will be available after the conclusion of the live presentation [6].

Sources

Earnings Report Biopharmaceutical